BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17574396)

  • 1. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
    Van LM; Hargreaves JA; Lennard MS; Tucker GT; Rostami-Hodjegan A
    Eur J Pharm Sci; 2007 Sep; 32(1):8-16. PubMed ID: 17574396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
    Van LM; Swales J; Hammond C; Wilson C; Hargreaves JA; Rostami-Hodjegan A
    Eur J Pharm Sci; 2007 May; 31(1):53-61. PubMed ID: 17387004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
    Van LM; Sarda S; Hargreaves JA; Rostami-Hodjegan A
    J Pharm Sci; 2009 Feb; 98(2):763-71. PubMed ID: 18543297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
    Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.
    Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA
    Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
    Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
    Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sodium ozagrel on the activity of rat CYP2D6.
    Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
    Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
    Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
    Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.
    Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL
    Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
    Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
    Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.
    Favreau LV; Palamanda JR; Lin CC; Nomeir AA
    Drug Metab Dispos; 1999 Apr; 27(4):436-9. PubMed ID: 10101136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.
    Lin LY; Di Stefano EW; Schmitz DA; Hsu L; Ellis SW; Lennard MS; Tucker GT; Cho AK
    Drug Metab Dispos; 1997 Sep; 25(9):1059-64. PubMed ID: 9311621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
    Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Eur J Pharm Sci; 2005 Nov; 26(3-4):334-40. PubMed ID: 16137870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.
    Dietrich M; Grundmann L; Kurr K; Valinotto L; Saussele T; Schmid RD; Lange S
    Chembiochem; 2005 Nov; 6(11):2014-22. PubMed ID: 16222729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.